市场监管总局禁止武汉用通医药有限公司收购山东北大高科华泰制药有限公司股权案

Core Viewpoint - The State Administration for Market Regulation has prohibited Wuhan Yuntong Pharmaceutical Co., Ltd. from acquiring equity in Shandong Beida Gaoke Huatai Pharmaceutical Co., Ltd. due to concerns over competition in the market for the drug, Poppy Alkaloid Injection [1] Group 1: Acquisition Details - Wuhan Yuntong signed an agreement to acquire 50% equity in Shandong Huatai Pharmaceutical in November 2018 and completed the equity change registration in March 2019 [1] - The acquisition involves the drug Poppy Alkaloid Injection, which is significant for public health [1] Group 2: Regulatory Actions - In January 2023, the State Administration for Market Regulation requested Wuhan Yuntong and its ultimate controller to submit a concentration of operators declaration [1] - In May 2023, the regulatory body raised competition concerns regarding the acquisition, indicating it could exclude or restrict competition in the domestic market for Poppy Alkaloid Injection [1] - In July 2023, the decision was made to prohibit the acquisition, mandating the parties involved to transfer the equity and terminate the raw material drug agency agreement within a specified timeframe [1]